The government has expressed interest in introducing an oral antiviral drug for COVID-19 by the end of the year, with Prime Minister Fumio Kishida saying that such treatments could become a “key trump card” in the prolonged, uphill battle against the coronavirus.
Selon les experts médicaux, le marché des vaccins contre le Covid-19 du Vietnam devrait connaître un taux de croissance élevé dans les années à venir.
La durée de recherche et de production du vaccin Nano Covax a été raccourcie au maximum possible afin d’avoir rapidement un vaccin anti-COVID-19 efficace.
As winter approaches and colder weather makes it even more difficult to adhere to social distancing measures, the odds of COVID-19 spreading still further seem to be inevitable. Still, despite having the highest infection rate in the world, there is growing optimism in the United States, thanks to the prospect of effective vaccines being developed in the not-too-distant future.
Une virologue de Hong Kong affirme que de nombreuses vies auraient pu être sauvées si la Chine n’avait pas censuré son travail, alors qu’elle a fui le pays par peur de représailles.
– Cells responsible for lasting ability to fight the virus were not found in those patients, Chinese scientists say
– Absence of the cells casts doubt on patients’ ability to produce the complete immune response needed for a vaccine to work
– China’s leading specialist Zhong Nanshan says researchers from the two countries can ‘learn a lot from each other’
– Last week’s announcement that Russia had approved a vaccine without large-scale trials has prompted widespread scepticism
BEIJING (Reuters) – A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
Oral form using ground-up pupae may prove effective against deadly disease. As scientists the world over scramble to develop a vaccine for the coronavirus, Kyushu University professor Takahiro Kusakabe and his team are working to develop a unique vaccine using silkworms.
Six vaccins potentiels contre le COVID-19, dont trois ont été développés en Chine, sont entrés dans la phase III des essais cliniques, a déclaré jeudi un haut responsable de l’Organisation mondiale de la santé (OMS).
Une usine de vaccins en Chine a obtenu les qualifications nécessaires pour produire en masse un vaccin contre le COVID-19.
Dans un communiqué de presse publié le 5 août, China National Biotec Group a annoncé qu’à la mi-juillet, sa première usine de production de vaccins contre le COVID-19 inactivés au monde, située à Beijing, avait passé des inspections conjointes de biosécurité organisées par les départements compétents et était désormais qualifiée pour mettre un vaccin en production de masse à tout moment. L’installation de production avait déjà obtenu une licence de production de vaccins contre le COVID-19 auparavant.
– 144 participants in mainland China will receive two shots of the BNT162b1 coronavirus vaccine candidate spaced by 21 days
– BioNTech among the first international biopharmaceutical companies to start clinical trial of a Covid-19 vaccine candidate in China
– The team has developed a vaccine which stops a key part of the infection process by preventing the coronavirus from attaching to human cells
– Johnson Lau of PolyU says residents of Hong Kong and Macau should be given priority when the vaccine hits market after successful trials
– Phase-two trial by team of Chinese scientists ‘induces significant neutralising antibody responses’, paper in peer-reviewed The Lancet reports
– Study out of Britain’s Jenner Institute finds antibodies are still high up to two months after vaccine administered
La Compagnie de vaccins et de production biologique No.1 (Vabiotech) a achevé le développement d’un vaccin potentiel contre le Covid-19.
